HomeNewsEnvironmentEpicentre of climate-change tech will move into India: Prashanth Prakash

Epicentre of climate-change tech will move into India: Prashanth Prakash

There’s a large opportunity in this space to build from India for the world, says the co-founder of venture capital major Accel India and Board member at ACT.

November 17, 2022 / 10:19 IST
Story continues below Advertisement
(Image: AP)
(Image: AP)

The Green Start-up Pledge (GSP), a collaboration between non-profit venture ACT For Environment and Boston Consulting Group (BCG), is looking to help the Indian start-up ecosystem transition towards a more sustainable future by integrating sustainability into its core principles.

Prashanth Prakash, the co-founder of Accel India and a Board member at ACT, says those start-ups that will commit to the cause of GSP will benefit from business-friendly frameworks and a resource platform for implementation. The market opportunity is huge.

Story continues below Advertisement

According to a report by the International Energy Agency (IEA), the global cleantech market will surpass the value of the oil market by 2030, rising to $870 billion from the $122 billion estimated at present. Excerpts from an interview:

What was the thought process behind setting up this pledge?

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show